Adding docetaxel to antiandrogen treatment improves progression-free survival (PFS) in prostate cancer patients with prostate-specific antigen (PSA) relapse.
Dr Andreas Josefsson (Sahlgrenska University Hospital, Göteborg, Sweden) presented the SPCG-14 study, a prospective, multicentre, phase 2 clinical trial of bicalutamide alone or with the addition of docetaxel in nonmetastatic prostate cancer with a rising PSA . This trial assessed whether any benefit is gained by adding docetaxel-based chemotherapy to hormonal therapy alone in the population of prostate cancer patients who have only biochemically relapsed disease after curative treatment (PSA doubling time is <12 months). The investigators hypothesised further that the approach is likely to be more effective at a time of minimal tumour burden, prior to radiographic relapse, resulting in minimisation of the overall burden of therapy and b...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« LUTS 2-year outcomes: aquablation versus TURP Next Article
Immuno-oncology + tyrosine kinase inhibitors in intermediate- and poor-risk mRCC »
Table of Contents: EAU 2020
Surgical Techniques and Safety
Prostate Cancer & Imaging
BPH & LUTS
Testis Cancer & Andrology
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.